XOMA Corporation (NASDAQ:XOMA)
Industry: Healthcare

OFF LIST - 2097 consecutive market days: OFF LIST as of 02/06/2008 Through 11/14/2016

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California.

Current Quote*
Last: $13.060
Change: -0.380
Book: $21.097
Volume: 78,321

As Of: 11/14 14:41 ET
*Quotes delayed by 20min.

Graphs for XOMA


3 Month Graph


6 Month Graph


1 Year Graph